Biotech News

Nektar Therapeutics Announces Third Quarter 2026 Financial Results

Nektar Therapeutics (NKTR)Nektar TherapeuticsEarnings

SAN FRANCISCO, Nov. 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update. Cash and investments in marketable securities on September 30, 2026, were $952.9 million as compared

Related news

Nektar Therapeutics

Immune-Regulatory Therapeutics Nektar Therapeutics develops biologic medicines that selectively modulate immune-cell pathways. Its current portfolio emphasizes regulatory T-cell biology for autoimmune and inflammatory diseases. Rezpegaldesleukin Rezpegaldesleukin is an IL-2 pathway agonist designed to expand and activate regulatory T...

Recent company news

Stock data

Close
32.54 USD
Market cap
1.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States